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From summary and commentary
The detailed dispensing database kept by
British Columbia in Canada enabled an
analysis of the factors associated with
sustained remission from opioid
dependence after being withdrawn from
methadone maintenance.
A slow taper of a year or more liberally
interspersed with stabilisation periods
seemed to offer the best chance of
avoiding relapse over the next 18 months.
Even then the great majority of taper
attempts were followed by relapse, and
overall fewer than 1 in 20 tapers ended in
treatment exit and sustained remission.
This entry is our analysis of a study considered particularly relevant to improving
outcomes from drug or alcohol interventions in the UK. The original study was not
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Based on detailed treatment records kept by the Canadian province of British Columbia, a slow
taper liberally interspersed with stabilisation periods offers the best chance of sustainably
withdrawing from methadone without severe relapse, but still very few manage to avoid this risk
– an argument for careful consideration and informed consent before making the attempt.
SUMMARY Long-term substitution of illegal opioids with the opioid medication methadone (a
treatment known as methadone maintenance) is the best established treatment for preventing
harm from dependence on heroin and allied drugs, but successfully terminating the treatment
has proved difficult.
Reviews have found that while withdrawal severity
can be ameliorated, very few patients complete the
process of tapering (gradual dose reduction)
methadone preparatory to treatment exit, and
relapse is common among those who do complete.
Nevertheless, methadone detoxification and
dose-tapering among maintained patients remain
common. Patients may choose to detoxify due to
what usually prove unrealistic expectations for
recovery, pressure from family or others, the
stigma associated with methadone, programme-
related factors, financial or travel difficulties, or to
see whether they can cope without treatment.
Their doctors may taper them for disciplinary
reasons or, in some jurisdictions, due to funding
constraints or regulations governing the treatment.
Despite extensive clinical experience, research
evidence is sparse, and important questions remain
regarding dose-tapering strategies. Are the
commonly recommended weekly dose reductions of 5–10% optimal? Should dose reduce
steadily without a break? Does it matter how long the patient had been in treatment before
tapering starts?
A detailed medication dispensing database covering the entire province of British Columbia in
Canada, including its many methadone-maintained patients, offered an opportunity to move
towards answering these questions. This data was drawn on to establish to what degree and
under what circumstances detoxifying from methadone was followed by sustained remission
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Treatment episodes in which
detoxification was attempted.
Orange dots are completed
detoxifications. Final dot
represents the fewer than 1 in 20
lastingly successful methadone
from opioid dependence. [As generally in the UK], in British Columbia methadone is
recommended to be delivered with a maintenance-oriented philosophy, provided by
general practitioners or specialised centres offering additional psychosocial care, and
dispensed and consumed under supervision at community pharmacies.
Over the 11 years from 1996 to 2006, records were sifted to identify all complete
episodes (ie, they started and ended during this period) of methadone maintenance
lasting unbroken for at least 31 days. Of these 25,545 episodes, in 14,602 after at least
12 weeks of treatment the dose was reduced, and remained reduced or was reduced
further for at least four weeks, indicating a tapering process rather than a dose
adjustment or some other reason for a fluctuating dose. However, many of these tapers
were quickly reversed, so the sample was sifted further to the 4,917 episodes which
terminated before July 2005 with a detoxification lasting at least four weeks – defined as
episodes where during the final four weeks of treatment the dose was still falling and/or
had decreased below 5 mg a day. The July 2005 cut-off meant every patient could be
tracked for 18 months after treatment ended, a period which it was known would include
the majority of relapses signalled by a return to treatment.
The study aimed to assess the degree to which these tapers were followed by sustained
remission. No direct measure of sustained remission was available, but a proxy was
constructed from the province’s records on hospital admissions and deaths. The criteria
were that the patient had tapered to 5 mg or less a day of methadone in the final week of
treatment and survived the following 18 months without re-entering treatment or having
to be admitted to hospital for reasons related to their opioid use. Primarily at issue was
what proportion of the 4,917 treatment episodes which ended with a taper were followed
by this indictor of sustained remission, and what features of the prior treatment appeared
to make this most likely. The features tested were:
• how long the patient had been in treatment before the taper started;
• how long the taper lasted from its start to the end of the treatment episode;
• how rapidly across the taper the dose typically decreased in proportional terms;
• as above, but how rapidly in absolute terms (ie, mg per week) the dose decreased; and
• how (dis)continuously the dose decreased during the taper – the degree to which the
taper was interrupted by weeks when the dose was held steady, measured as the number
of weeks which included a dose decrease in proportion to the duration of the taper in
weeks.
• how steeply the dose decreased during the weeks when it fell.
The results were adjusted for other possible influences on the chances of sustained
remission, including maximum weekly dose during treatment and treatment ‘adherence’ –
the proportion of their intended doses actually taken by the patient.
Main findings
Of the 4,917 treatments which ended with a detoxification, around a quarter – 1305 –
ended with a daily methadone dose of 5 mg or less. Of these effectively completed
detoxifications, about half (646) resulted in apparently sustained remission, representing
just over 1 in 8 of the 4,917 treatments which ended with detoxification, under 1 in 20 of
the 14,602 in which a taper was attempted at some time ( chart), and 1 in 40 of all
25,545 episodes completed during the study period.
In the following 18 months the ‘unsuccessful’ half of
completed detoxifications were usually followed by
treatment re-entry (458 of 659 episodes) or opioid-related
hospitalisations (319 episodes). Another 29 patients died,
the equivalent of about 1.5 deaths per 100 patients over a
year.
The analysis then identified treatment factors related to
the success of the 4,917 treatments which ended with
detoxification, adjusting for other influences in the attempt
to isolate what may be cause and effect relationships.
Because they overlapped so much, factors characterising in
different ways the rapidity of detoxification had to be
analysed separately, meaning their independent
contributions to securing lasting remission could not
readily be teased out.
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tapers.Variations in the success rate of treatment episodes
ending in a detoxification were best accounted for by
factoring in how long the taper lasted. Adjusting for other influences, the longer the
taper (only tapers lasting at least four weeks were assessed) the greater the
chances of sustained remission. Relative to tapers of under 12 weeks, those lasting
12 weeks to a year were 3.6 times more likely to be followed by sustained
remission, those lasting over a year, 6.7 times. As well as duration, the rapidity of
the decrease in dose was also related to the chances of sustained remission. A
relatively steep weekly decrease across the entire taper of over 4% a week was
nearly 27% less likely to be followed by sustained remission than more gradual
tapers.
The most complex analysis combined the continuity of the taper (proportion of
weeks when the dose reduced) with the rapidity of the dose decrease during the
weeks when the dose did reduce. Holding doses steady on between half to three-
quarters of the weeks of the taper (the most common pattern) was followed by the
highest remission rate. Both proportionately more and proportionately fewer
steady-state weeks were associated with a lower chance of lasting remission. Unlike
the dose change over the whole taper, a relatively steep step down during the
weeks when the dose fell was associated with a higher chance of sustained
remission. Steps down between 5% and 15% were associated with twice the chance
of lasting remission of the more typical step down of under 5%; further steepening
the step was not associated with further increases in lasting remission.
Once other factors were adjusted for, how long (after 12 weeks) the patient had
been in treatment before tapering was unrelated to the chances of it being followed
by sustained remission. In contrast, how ‘compliant’ the patient had been with
taking their methadone during the entire treatment episode was consistently
related to a higher chance of sustained remission. Additionally, treatment episodes
during which daily doses had reached or exceeded 60 mg were less likely to see an
end-of-treatment taper being followed by sustained remission than when the dose
had remained lower.
Being young (under 25), male, and in some analyses relatively healthy in the
run-up to treatment, were also associated with greater chances of sustained
remission after ending treatment with detoxification.
Even when the withdrawal process was relatively optimal, the chances of a lastingly
successful end to opioid use problems were small. Tapers lasting over a year still
failed to stick in 78% of cases and as did 87% when the taper rate was typically
under 4%. Leavening the taper with a half to three-quarters of weeks when dose
remained stable was still followed by an 83% ‘failure’ rate in the 18 months after
treatment ended.
The authors’ conclusions
Analyses adjusted for other influences suggest that regardless of how early in
treatment they are initiated, longer and more gradual tapers with dose decreased
in only a quarter to half of the weeks have a substantially higher chance of success
than other tapering schedules.
The overall rate of success was just 13% among the 4,917 treatment episodes
selected for the study, 4.4% among all episodes during which a taper was started,
and 2.5% among all completed episodes – poor outcomes consistent with previous
findings. Methadone maintenance patients have a variety of reasons for seeking to
achieve a drug-free state, but need to be informed of the high risks of relapse and
adverse health outcomes. Such are the risks that regulatory bodies should consider
mandating informed consent before tapering can be started.
In interpreting these findings, it is important to recognise that outcomes in any
study which tracks real-world processes may not be caused by the factors
highlighted by the study, but by others which these research designs are unable to
fully eliminate or adjust for. For example, it could be that steeper tapers were
disciplinary in nature[, the implication being that they were applied to ‘difficult’
patients and/or during treatments which do not follow clinical guidelines – factors
which (rather than the steepness of the taper) may have accounted for poorer
outcomes]. Conversely, episodes with more gradual tapering may be indicative of
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individualised care, with doses titrated and tapered according to individual
needs in suppressing withdrawal symptoms. [In this scenario, individualised
care may be the salient factor, and though expressed more often in gradual
tapering, might in other cases result in a steeper decline if that suits the
individual best.]
Another example of how the results need to be carefully interpreted may be
the unexpected relationship between maximum dose during treatment and
the chances of sustained remission after a treatment-end detoxification.
Doses of at least 60 mg are recommended and help retain patients in
treatment, yet the featured analysis found these associated with a lower
chance of sustained remission. The explanation could be that an
individualised approach to treatment results in more severely dependent
patients being prescribed higher doses. In this scenario, maximum
maintenance dose is not a causal factor, but merely a marker of the severity
which impedes sustained remission after leaving treatment.
It should also be acknowledged that the criteria for successful detoxification
used by the study are more directly indicative of medical safety and patient
stability following treatment than of relapse, which may occur without
hospitalisation, treatment re-entry, or death. Also, the findings emerged from
British Columbia, where treatment is heavily subsidised and characterised by
a maintenance philosophy, and licensed doctors can provide treatment
outside the context of specialised centres.
 COMMENTARY In a UK-like treatment policy and practice
context, the finding that fewer than 1 in 20 treatment episodes featuring a
methadone taper ended with detoxification and no subsequent return to
treatment, hospitalisation, or death, is likely to over-estimate the
relapse-free success rate after terminating methadone. Many other patients
will have relapsed without notching up these indicators. These kinds of
findings should temper the recent enthusiasm in UK government circles (one
embodied in treatment success indicators) for promoting more rapid and
widespread exit from methadone maintenance and allied treatments.
The year after the featured study was published the literature comparing
methadone-based detoxification with alternatives was reviewed according to
the rigorous protocols of the Cochrane Collaboration. Reviewers concluded
that “slow tapering with temporary substitution of long-acting opioids, could
reduce withdrawal severity. Nevertheless, the majority of patients relapsed to
heroin use.”
In line with these findings, UK studies (1 2) have implied that “to save the
lives of patients dependent on heroin or similar drugs, they should be
engaged and retained in substitute prescribing programmes like methadone
maintenance until there is little risk of their relapsing after leaving”.
However, how to establish there is little risk of relapse remains unclear. The
featured study contributes significantly to making this clearer, suggesting
that though remaining low, the success rate is improved when methadone is
tapered over a long period – a year or more – liberally interspersed with
periods of stabilisation, with the dose reducing overall at less than 5% a
week. UK clinical guidelines are not entirely in line with these findings. They
suggest that “Following stabilisation on methadone the dose can be reduced
at a rate which will result in zero in around 12 weeks. This is usually a
reduction of around 5 mg every one or two weeks” – briefer and possible also
steeper than the featured study found most effective.
The finding that the chances of success were not significantly lower among
patients longer in treatment counters fears that prolonged treatment is both
a sign of and a contributor to patients being ‘stuck’ on methadone.
Adjusting the methadone taper is not the only way to attempt to ease the
transition out of substitute prescribing treatment. Other strategies include
transition first to buprenorphine, an opioid medication which can substitute
for illegal opioids but seems easier to withdraw from than methadone (1 2 3).
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Patients who have chosen rather than been forced to detoxify, who do
so after a period of stability, and who are considered suitable by staff,
also have the greatest chance of staying free of opioid drugs.
The authors of the featured article stressed their findings may be
dependent on the British Columbian context. Part of that context is the
availability of services which can boost what has become known as
‘recovery capital’ – resources which raise the chances of sustainably
ending dependent substance use, the implications of which were
recognised in 1926 in a report generally recognised as the foundation
for opioid maintenance in Britain. Its authors speculated that had
there been sufficient support available (they were thinking of
residential recovery centres) and enough leverage to get addicts to use
it, maintenance might no longer be needed. Similarly, today it can
reasonably be speculated that in British Columbia as in the UK, failure
to provide (among other services) high quality relapse-preventing
housing, employment, family reconciliation services, and mental health
care, is one reason why terminating methadone and allied treatments
is so often followed by relapse and the risks entailed in a return to
regular illicit opioid use. However, those resources would need to be
substantial (1 2) to match the power of continuing substitute
prescribing. Short of an ideal set of wrap-around support services,
retention in substitute prescribing programmes is internationally
recognised as the best way to safeguard both the patients and the
communities they live in.
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